fda pulls tirzepatide Compounded versions of (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said Tirzepatide Wins FDA Approval for

GlyT1 inhibition can facilitate NMDA receptor activity and is therefore primarily conceived as a potential remedy against the cognitive and affective deficiencies in schizophrenia, which are due to an underlying impairment in NMDA receptor signalling

The Vitamin B12 Shot retains more of the vitamin versus supplements which lose up to 88 percent of the vitamin

the gut and brain adapt to a given exposure over a few weeks, so introducing the drug at a low dose and stepping up gradually lets tolerance develop before the next increment

GLP-1s are years ahead of any other potential breakthrough therapies for addiction treatment in the pipeline (with the partial exception of the new Vertex non-addictive painkiller, suzetrigine)

Depression has many contributing factors